NDA 021136 · Chirhoclin
Secreflo
Secretin Synthetic Porcine · Intravenous
OrphanDiscontinuedLast checked: Nov 20, 2026Latest source record: Oct 26, 2016 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2002
Apr 4, 2002
Approved uses
2
Original approval plus efficacy supplements
Registered trials
1
1 Phase 3, 0 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Therapeutic areas: Ophthalmology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 1, 2002 Supplement 1 · Efficacy · priority review ReviewLetterLabel
- Apr 4, 2002 Original approval · Type 3 - New Dosage Form OrphanLabelReviewLetter
1 products under this application
- SECREFLO · SECRETIN SYNTHETIC PORCINE 16MCG/VIAL · FOR SOLUTION, INTRAVENOUS · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Secretin Synthetic Porcine" as an intervention, any sponsor and status, largest first.
- Secretin for the Treatment of AutismPivotal-lookingCompleted
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)NIH
NCT00065962 · 85 participants · Start Jun 1999
Drug: secretin, synthetic porcine; secretin, biologically derived porcine · For: Autism
Sites: Denver, Colorado; Seattle, Washington
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
No PubMed clinical studies matched.
Sponsor: Chirhoclin
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.